Overview

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

Status:
Active, not recruiting
Trial end date:
2021-12-17
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to examine the effect of LCIG relative to that of OMT on NMS associated with PD.
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie
Treatments:
Carbidopa
Carbidopa, levodopa drug combination
Levodopa